Girdlestone procedure: when and why

被引:33
|
作者
Cordero-Ampuero, Jose [1 ]
机构
[1] Univ Autonoma Madrid, Sch Med, Hosp Univ Princesa, Dept Orthopaed Surg, Madrid, Spain
关键词
Functional results; Girdlestone; Infected hip; PROSTHETIC JOINT INFECTION; RESECTION ARTHROPLASTY; ORAL ANTIBIOTICS; REIMPLANTATION; SUPERIOR; THERAPY;
D O I
10.5301/HIP.2012.9568
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Girdlestone is one of the options for treating an infected hip arthroplasty (along with isolated antibiotics, debridement, and one or two-stage exchange). The choice must be based on a list of previous considerations. Results of girdlestone: Major differences among different series are reported in literature: from 13% to 83% of patients are satisfied with the result. Healing of infection is attained in 80% to 100% of patients, but figures are worse in special subsets (rheumatoid arthritis, enterococcal and methicillin-resistant infections, or when cement is retained). Pain is reported as severe in 16% to 33% of patients, moderate in 24% to 53% and mild in 76%, while only some authors refer to "satisfactory pain relief". Up to 45% of geriatric patients are unable to walk and only 29% walk independently. The literature reports Harris Hip scores from 25 to 64. Indications for girdlestone: Absolute indications: non-ambulatory patients because of other problems or diseases, and impossible reimplantation (2nd-stage surgery) (unacceptable anaesthetic or surgical risk, technical difficulties, patient rejection). Relative indications: Dementia (risk of dislocation vs. severely reduced walking ability), immunocompromise (up to what degree of immune impairment do we accept to take the risk?), intravenous drug abuse (how can you prove it?)
引用
收藏
页码:S36 / S39
页数:4
相关论文
共 50 条
  • [21] Protein supplementation in critical illness: why, when and how?
    Bels, Julia L. M.
    Abdelhamid, Yasmine Ali
    van de Poll, Marcel C. G.
    CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2023, 26 (02) : 146 - 153
  • [22] Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How?
    Kotsifa, Evgenia
    Vergadis, Chrysovalantis
    Vailas, Michael
    Machairas, Nikolaos
    Kykalos, Stylianos
    Damaskos, Christos
    Garmpis, Nikolaos
    Lianos, Georgios D.
    Schizas, Dimitrios
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (03):
  • [23] Nonsurgical therapy for teeth and implants-When and why?
    Lang, Niklaus P.
    Salvi, Giovanni E.
    Sculean, Anton
    PERIODONTOLOGY 2000, 2019, 79 (01) : 15 - 21
  • [24] Comparison of the results of the Girdlestone pseudarthrosis with reimplantation of a total hip replacement
    J. Schröder
    D. Saris
    P. P. Besselaar
    R. K. Marti
    International Orthopaedics, 1998, 22 : 215 - 218
  • [25] Analysis of clinical data in patients with Girdlestone arthroplasty: a new score
    Molfetta, L.
    Bassetti, M.
    Benvenuti, M.
    Caldo, D.
    HIP INTERNATIONAL, 2007, 17 (03) : 170 - 175
  • [26] Avoiding complacency when treating uncontrolled seizures: why and how?
    Amin, Ushtar
    Benbadis, Selim R.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2020, 20 (03) : 227 - 235
  • [27] When to start and stop caffeine and why respiratory status matters
    Davis, Peter G.
    SEMINARS IN FETAL & NEONATAL MEDICINE, 2020, 25 (06)
  • [28] The need for treatment against human parechoviruses: how, why and when?
    Wildenbeest, Joanne G.
    Harvala, Heli
    Pajkrt, Dasja
    Wolthers, Katja C.
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2010, 8 (12) : 1417 - 1429
  • [29] TB hip case report: a girdlestone, a forgotten yet successful operation
    Nabeela Adam
    Discover Medicine, 2 (1):
  • [30] Beyond low-density lipoprotein cholesterol: why, who and when
    Chang, Christopher Ngai Kin
    How, Choon How
    Tavintharan, Subramaniam
    SINGAPORE MEDICAL JOURNAL, 2012, 53 (09) : 566 - 568